Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 1, 2012, Pages 31-39

  Villarinho, Jardel Gomes ^a   Fachinetto, Roselei ^a   Pinheiro, Francielle de Vargas ^a   Sant'Anna, Gabriela da Silva ^a   Machado, Pablo ^a   Dombrowski, Patrícia Andréia ^b   Cunha, Cláudio da ^b   Cabrini, Daniela de Almeida ^b   Martins, Marcos AntÔnio Pinto ^a   Bonacorso, Helio Gauze ^a   Zanatta, Nilo ^a   Rubin, Maribel Antonello ^a   Ferreira, Juliano ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Depression; Moclobemide; Monoamine metabolism; Reversible MAO A inhibitor

Indexed keywords

2 (3,4 DIMETHOXYPHENYL) 4,5 DIHYDRO 1H IMIDAZOLE; AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DIAZEPAM; DOPAMINE; HALOPERIDOL; METHYSERGIDE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NORADRENALIN; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN CORTEX; CATECHOLAMINE METABOLISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HIPPOCAMPUS; IMMOBILIZATION; LOCOMOTION; MALE; MOTOR COORDINATION; MOUSE; NEUROMODULATION; NONHUMAN; SEROTONIN METABOLISM; SEROTONINERGIC SYSTEM; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ANIMALS; ANISOLES; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BRAIN; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HALOPERIDOL; IMIDAZOLINES; ISOENZYMES; KINETICS; MALE; METHYSERGIDE; MICE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS; PIPERAZINES; PYRIDINES;

EID: 84864528267     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.04.007     Document Type: Article

References (57)

1. Archer J. Tests for emotionality in rats and mice: a review. Anim Behav 1973, 21:205-235.
2. Bach A.W.J., Lan N.C., Johnson D.L., Abell C.W., Bembenek M.E., Kwan S.-W., et al. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci 1988, 85:4934-4938.
3. Basso A.M., Gallagher K.B., Bratcher N.A., Brioni J.D., Moreland R.B., Hsieh G.C., et al. Antidepressant-like effect of D(2/3) receptor-, but not D(4) receptor-activation in the rat forced swim test. Neuropsychopharmacology 2005, 30:1257-1268.
4. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-151.
5. Blier P., Ward N.M. Is there a role for 5-HT1A agonists in the treatment of depression?. Biol Psychiatry 2003, 53:193-203.
6. Burkard W.P., Bonetti E.P., Da Prada M., Martin J.R., Polc P., Schaffner R., et al. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 1989, 248:391-399.
7. 50) of an enzymatic reaction. Biochem Pharmacol 1973, 22:3099-3108.
8. Cryan J.F., Mombereau C., Vassout A. The tail suspension test for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005, 29:571-625.
9. Da Prada M., Kettler R., Keller H.H., Burkard W.P., Muggli-Maniglio D., Haefely W.E. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 1989, 248:400-414.
10. Dailly E., Chenu F., Renard C.E., Bourin M. Dopamine, depression and antidepressants. Fundam Clin Pharmacol 2004, 18:601-607.
11. 3 dopamine receptor agonist. Brain Res Bull 2007, 74:58-65.
12. Duarte F.S., Lach G., Martins P.R.C., Romeiro G.A., Lima T.C.M. Evidence for the involvement of the monoaminergic system in the antidepressant-like action of two 4-amine derivatives of 10,11-dihydro-5H-dibenzo [a, d] cycloheptane in mice evaluated in the tail suspension test. Prog Neuro-Psychopharmacol Biol Psychiatry 2008, 32:368-374.
13. Dunham N.W., Miya T.S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc 1957, 46:208-209.
14. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007, 64:327-337.
15. Elhwuegi A.S. Central monoamines and their role in major depression. Prog Neuro-Psychopharmacol Biol Psychiatry 2004, 28:435-451.
16. Feiger A.D. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharmacol Bull 1996, 32:659-665.
17. Feiger A.D., Heiser J.F., Shrivastava R.K., Weiss K.J., Smith W.T., Sitsen J.M., et al. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry 2003, 64:243-249.
18. Ferraz A.C., Anselmo-Franci J.A., Perosa S.R., Castro-Neto E.F., Bellissimo M.I., Oliveira B.H., et al. Aminoacid and monoamine alterations in the cerebral cortex and hippocampus of mice submitted to ricinine-induced seizures. Pharmacol Biochem Behav 2002, 72:779-786.
19. Godoy M.C., Fighera M.R., Souza F.R., Flores A.E., Rubin M.A., Oliveira M.R., et al. Alpha 2-adrenoceptors and 5-HT receptors mediate the antinociceptive effect of new pyrazolines, but not of dipyrone. Eur J Pharmacol 2004, 496:93-97.
20. Graeff F.G., Netto C.F., Zangrossi H. The elevated T-maze as an experimental model of anxiety. Neurosci Biobehav Rev 1998, 23:237-246.
21. Griebel G., Perrault G., Sanger D.J. Behavioural profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs. Psychopharmacology 1997, 131:180-186.
22. Griebel G., Curet O., Perrault G., Sanger D.J. Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine-oxidase activity and monoamine levels. Neuropharmacology 1998, 37:927-935.
23. 1A receptors. J Neurosci 1998, 18:10150-10156.
24. Hamner M.B., Diamond B.I. Plasma dopamine and norepinephrine correlations with psychomotor retardation, anxiety, and depression in non-psychotic depressed patients: a pilot study. Psychiatry Res 1996, 64:209-211.
25. Harfenist M., Heuser D.J., Joyner C.T., Batchelor J.F., White H.L. Selective inhibitors of monoamine oxidase. 3. Structure-activity relationship of tricyclics bearing imidazoline, oxadiazole, or tetrazole groups. J Med Chem 1996, 39:1857-1863.
26. Hascoët M., Bourin M., Colombel M.C., Fiocco A.J., Baker G.B. Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice. Pharmacol Biochem Behav 2000, 65:339-344.
27. Holmes A., Rodgers R.J. Prior exposure to the elevated plus-maze sensitizes mice to the acute behavioral effects of fluoxetine and phenelzine. Eur J Pharmacol 2003, 459:221-230.
28. Jenkins S.W., Robinson D.S., Fabre L.F., Andary J.J., Messina M.E., Reich L.A. Gepirone in the treatment of major depression. J Clin Psychopharmacol 1990, 10:77S-85S.
29. Johnston J.P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968, 17:1286-1297.
30. Kitanaka N., Kitanaka J., Takemura M. Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-A inhibitor, through alteration of the 5-hydroxytriptamine turnover in the striatum. Neuroscience 2005, 130:295-308.
31. Kitanaka N., Kitanaka J., Takemura M. Modification of morphine-induced hyperlocomotion and antinociception in mice by clorgyline, a monoamine oxidase-A inhibitor. Neurochem Res 2006, 31:829-837.
32. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987, 92:180-185.
33. Liu J., Garza J.C., Bronner J., Kim C.S., Zhang W., Lu X.Y. Acute administration of leptin produces anxiolytic-like effects: a comparison with fluoxetine. Psychopharmacology 2010, 207:535-545.
34. López-Muñoz F., Álamo C., Juckel G., Assion H.-J. Half a century of antidepressnat drugs - on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: Monoamine oxidase inhibitors. J Clin Psychopharmacol 2007, 27:555-559.
35. Machado D.G., Kaster M.P., Binfaré R.W., Dias M., Santos A.R.S., Pizzolatti M.G., et al. Antidepressant-like effect of the extract from leaves of Schinus molle L. in mice: evidence for the involvement of the monoaminergic system. Prog Neuro-Psychopharmacol Biol Psychiatry 2007, 31:421-428.
36. Matsumoto T., Suzuki O., Furuta T., Asai M., Kurokawa Y., Rimura Y., et al. A sensitive fluorometric assay for serum monoamine oxidase with kynuramine as substrate. Clin Biochem 1985, 18:126-129.
37. McGrath P.J., Stewart J.W., Quitkin F.M., Wager S., Jenkins S.W., Archibald D.G., et al. Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. J Clin Psychopharmacol 1994, 14:347-352.
38. Meyer J.H., Ginovart N., Boovariwala A., Sagrati S., Hussey D., Garcia A., et al. Elevated monoamine oxidase A levels in the brain. Arch Gen Psychiatry 2006, 63:1209-1216.
39. Millan M.J. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. Eur J Pharmacol 2004, 500:371-384.
40. Miura H., Naoi M., Nakahara D., Ohta T., Nagatsu T. Effects of moclobemide on forced-swimming stress and brain monoamine levels in mice. Pharmacol Biochem Behav 1996, 53:469-475.
41. Naderi N., Haghparast A., Saber-Tehrani A., Rezaii N., Alizadeh A.M., Khani A., et al. Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol Biochem Behav 2008, 89:64-75.
42. Nash J., Nutt D. Antidepressants. Psychiatry 2007, 6:289-294.
43. Papakostas G.I. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol 2006, 16:391-402.
44. 2+ antagonist, on activity of MAO inhibitors, N-acetylserotonin and melatonin in the mouse tail suspension test. Int J Neuropsychopharmacol 1998, 1:35-40.
45. Robinson D.S. Monoamine oxidase inhibitors: a new generation. Psychopharmacol Bull 2002, 36:124-138.
46. 1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990, 10:67S-76S.
47. Rodrigues A.L.S., Rosa J.M., Gadotti V.M., Goulart E.C., Santos M.M., Silva A.V., et al. Antidepressant-like and antinociceptive-like actions of 4-(4'-chlorophenyl)-6-(4?-methylphenyl)-2-hydrazinepyrimidine Mannich base in mice. Pharmacol Biochem Behav 2005, 82:156-162.
48. Roy A., Pickar D., Linnoila M., Potter W.Z. Plasma norepinephrine level in affective disorders. Relationship to melancholia. Arch Gen Psychiatry 1985, 42:1181-1185.
49. Sant'Anna G.S., Machado P., Sauzem P.D., Rosa F.A., Rubin M.A., Ferreira J., et al. Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett 2009, 19:546-549.
50. Skolnick P., Popik P., Janowsky A., Beer B., Lippa A.S. "Broad spectrum" antidepressants: is more better for the treatment of depression?. Life Sci 2003, 73:3175-3179.
51. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
52. Steru L., Chermat R., Thierry B., Mico J.A., Lenegre A., Steru M., et al. The automated Tail Suspension Test: a computerized device which differentiates psychotropic drugs. Prog Neuro-Psychopharmacol Biol Psychiatry 1987, 11:659-671.
53. Thase M.E., Trivedi M.H., Rush A.J. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995, 12:185-219.
54. Tonello R., Villarinho J.G., Sant'anna G.S., Tamiozzo L., Machado P., Trevisan G., et al. The potential antidepressant-like effect of imidazoline I(2) ligand 2-BFI in mice. Prog Neuro-Psychopharmacol Biol Psychiatry 2012, 37:15-21.
55. Wong M.-L., Licinio J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 2004, 3:136-151.
56. Youdim M.B.H., Edmondson D., Tripton K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006, 7:295-309.
57. Zomkowski A.D.E., Rosa A.O., Lin J., Santos A.R.S., Calixto J.B., Rodrigues A.L.S. Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test. Brain Res 2004, 1023:253-263.